**Core Concept**
The bcr-abl gene translocation is a type of chromosomal abnormality involving the fusion of the breakpoint cluster region (bcr) gene on chromosome 22 with the abl gene on chromosome 9. This genetic rearrangement leads to the formation of a constitutively active tyrosine kinase, which plays a key role in the pathogenesis of a specific type of leukemia.

**Why the Correct Answer is Right**
The bcr-abl gene translocation is characteristically seen in Chronic Myeloid Leukemia (CML) and some cases of Acute Lymphoblastic Leukemia (ALL). The translocation results in the formation of a chimeric protein with constitutive tyrosine kinase activity, which drives the proliferation of leukemic cells. The bcr-abl fusion protein is resistant to normal regulatory mechanisms, leading to uncontrolled cell growth and disease progression.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is not correct because the bcr-abl gene translocation is not characteristic of Acute Myeloid Leukemia (AML), although some cases of AML may exhibit similar genetic abnormalities.
* **Option B:** This option is not correct because the bcr-abl gene translocation is not a hallmark of Lymphoma, although some cases of lymphoma may involve similar genetic rearrangements.
* **Option D:** This option is not correct because the bcr-abl gene translocation is not characteristic of Multiple Myeloma, which is a different type of hematological malignancy.

**Clinical Pearl / High-Yield Fact**
The bcr-abl gene translocation is a diagnostic hallmark of CML, and its detection is critical for establishing a diagnosis and guiding treatment decisions. The presence of the bcr-abl fusion protein can be detected using molecular diagnostic techniques, such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH).

**Correct Answer:** C.